Authors
Latest:
Exploring a Time-to-Relapse Analysis for Rituximab and Transplant in MCLPeter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.
Latest:
Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for TrialsBeitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Latest:
BrECADD Shows Promise as New Standard for Advanced Hodgkin Lymphoma TreatmentPeter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.
Latest:
Improving Biomarker Discovery and Development in Urothelial CarcinomaPetros Grivas, MD, PhD, discusses the challenge with biomarker discovery currently in the treatment landscape of urothelial carcinoma.
Latest:
The Future of Squamous Cell Lung Cancer TreatmentPeter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Latest:
BRAF Testing Important for Clinical Decision-Making in Metastatic MelanomaWith the continuously expanding landscape of treatment options for advanced and/or metastatic melanoma, it is becoming increasingly important to understand the patient-specific oncogenic drivers as a means of selecting treatments.
Latest:
Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast CancerPeter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.<br />
Latest:
Promising Findings for Daratumumab Plus VRd in Multiple MyelomaPeter M. Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses efficacy and updated safety findings of a safety run-in cohort from the phase II Griffin trial, a randomized study of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-Vrd) versus Vrd in patients with newly diagnosed multiple myeloma eligible for high-dose therapy and autologous stem cell transplantation, during the 2018 ASH Annual Meeting.
Latest:
Expert Perspectives on the Current Role of CAR-T Cell Therapy in Patients with Mantle Cell Lymphoma (MCL)Dr Peter Martin discusses the impact of CAR-T cell therapy in patients with MCL and provides a brief review of key efficacy data from the ZUMA-2 trial.
Latest:
Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCCPeter R. Galle, MD, discusses the findings that came from the phase III IMbrave 150 clinical trial, which evaluated the combination of atezolizumab plus bevacizumab versus the standard of care, sorafenib, as frontline treatment of patients with unresectable hepatocellular carcinoma.
Latest:
Validation of a 46-Gene CCP RNA Signature for Predicting Prostate Cancer DeathPeter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Latest:
Evolving Treatments in Newly Diagnosed Multiple Myeloma (NDMM)In this companion article, Dr Peter Voorhees provides insights into effective management of patients with newly diagnosed multiple myeloma (NDMM).
Latest:
Observation Versus Treatment in Men with Prostate CancerPeter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <
Latest:
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder CancerPetros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Latest:
Learning From Negative Clinical Trials in Pancreatic CancerPhilip A. Philip, MD, PhD, professor of oncology and pharmacology, Karmanos Cancer Institute, Wayne State University, discusses how researchers in the pancreatic cancer field can learn from recent negative clinical trials.
Latest:
Triplet Therapy for Multiple MyelomaPhilip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.
Latest:
Toxicities Associated With Lenalidomide for Multiple MyelomaPhilip McCarthy, MD, professor of oncology, director, Blood and Marrow Transplant Center, Department of Medicine, Roswell Park Cancer Institute, discusses the toxicities associated with lenalidomide for multiple myeloma in the CALGB 100104 study.
Latest:
Current Research on Pancreatic CancerPhilip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses current research on pancreatic cancer, as well as funding, awareness, and treatment options.
Latest:
Discovering Patterns in Breast Cancer RatesPhilip S. Rosenberg, PhD, senior investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, discusses a study that examined patterns in breast cancer rates.
Latest:
PD-1 Inhibitors for Hematologic MalignanciesPhilippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
Latest:
Immune Correlates of Pathologic Response in Bladder Cancer Patients Undergoing ChemotherapyPhillip Abbosh, MD, PhD, assistant professor, Fox Chase Cancer Center, discusses immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy.
Latest:
Responses Improved for Newly Diagnosed Myeloma in Phase III CASSIOPEIA TrialPhillipe Moreau, MD, discusses the results from the randomized, open-label, multicenter phase III CASSIOPEIA trial. The results of the trial led to a priority review designation from the FDA for the combination of daratumumab plus bortezomib, thalidomide, and dexamethasone for patients with treatment-naïve multiple myeloma who are candidates for autologous stem cell transplant.
Latest:
Outcomes of Autologous Stem Cell Transplantation in Elderly Patients With Multiple MyelomaPhyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses a study of outcomes of autologous stem cell transplantation in very elderly patients with multiple myeloma.
Latest:
Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCCPierre Gholam, MD, discusses the phase 3 RATIONALE-301 study of frontline tislelizumab vs sorafenib for patients with hepatocellular carcinoma.
Latest:
Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple MyelomaPieter Sonneveld, MD, PhD, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.
Latest:
Factors Impacting Induction Therapy Selection in AMLPinkal Desai, MD, discusses the factors a practicing physician should consider when selecting an appropriate induction therapy for patients with acute myeloid leukemia.
Latest:
Dr. Piyush Agarwal on Recognizing, Diagnosing, and Treating Penile CancerAgarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.
Latest:
Evaluating the Potential for CAR T Cells as Treatment of Solid TumorsPrasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.
